Published in Springer Semin Immunopathol on January 01, 1998
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol (2003) 1.36
Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy (2010) 0.84
Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease. Biol Blood Marrow Transplant (2009) 0.76
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med (1989) 15.15
Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (1985) 14.39
Signalling downstream of activated mammalian Notch. Nature (1995) 11.08
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (1989) 7.60
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell (1985) 7.17
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A (1993) 5.92
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 5.28
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A (1991) 5.02
Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science (1994) 4.87
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol (1988) 4.55
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med (1984) 4.47
Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A (1975) 4.21
The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell (1989) 4.16
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med (1996) 4.07
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med (1996) 3.94
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A (1993) 3.66
Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol (1974) 3.58
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet (1994) 3.56
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene (1988) 3.42
Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis. N Engl J Med (1973) 3.33
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med (1984) 2.93
IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol (1992) 2.89
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer (1978) 2.81
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med (1997) 2.76
Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res (1981) 2.74
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J Exp Med (1977) 2.65
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol (1990) 2.58
X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet (1975) 2.57
Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology (1987) 2.53
Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation (1985) 2.34
HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science (1993) 2.28
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer (1985) 2.23
Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med (1979) 2.21
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell (1990) 2.20
Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A (1996) 2.18
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol (1992) 2.14
HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer (1984) 2.14
Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation (1990) 2.13
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol (1992) 2.09
An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med (1994) 2.02
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.99
The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A (1997) 1.98
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol (1996) 1.97
All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol (1993) 1.92
HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature (1980) 1.90
The switch between latency and replication of Epstein-Barr virus. J Infect Dis (1990) 1.89
Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr (1991) 1.85
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85
Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood (1995) 1.84
Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med (1998) 1.80
Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells. J Virol (1992) 1.77
Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol (1989) 1.77
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol (1993) 1.77
Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol (1985) 1.76
The Epstein-Barr virus proteins. Adv Cancer Res (1988) 1.74
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood (1995) 1.73
The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72
Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood (1988) 1.72
BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood (1996) 1.69
Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest (1984) 1.63
HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A (1980) 1.60
Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood (1986) 1.60
Quantitative evaluation of Epstein-Barr-virus-infected mononuclear peripheral blood leukocytes in infectious mononucleosis. N Engl J Med (1977) 1.59
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol (1993) 1.58
Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology (1992) 1.53
Donor T cells to treat EBV-associated lymphoma. N Engl J Med (1994) 1.53
On a mechanical method of correcting photographic records obtained from the capillary electrometer. J Physiol (1912) 80.05
The temperature-coefficient of the rate of conduction in nerve. J Physiol (1908) 17.15
On the transference of the propagated disturbance from nerve to muscle with special reference to the apparent inhibition described by Wedensky. J Physiol (1911) 14.92
The effect of alcohol on the excitation, conduction and recovery processes in nerve. J Physiol (1913) 11.02
On the recovery of muscle and nerve after the passage of a propagated disturbance. J Physiol (1910) 10.66
The excitable substances of amphibian muscle. J Physiol (1907) 9.59
An analysis of changes and differences in the excitatory process of nerves and muscles based on the physical theory of excitation. J Physiol (1910) 7.14
On summation of propagated disturbances in the claw of astacus, and on the double neuro-muscular system of the adductor. J Physiol (1917) 6.57
On the rate of development of the excitatory process in muscle and nerve. J Physiol (1908) 6.51
The "all or none" contraction of the amphibian skeletal muscle fibre. J Physiol (1909) 6.00
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 5.28
On the optimal electric stimuli of normal and curarised muscle. J Physiol (1906) 3.95
On the relation between the electric disturbance in muscle and the propagation of the excited state. J Physiol (1909) 3.60
On the rate of variation of the exciting current as a factor in electric excitation. J Physiol (1907) 3.03
The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest (1992) 2.51
The analysis of complex excitable tissues by their response to electric currents of short duration. J Physiol (1907) 2.18
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant (2013) 2.04
Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood (1989) 1.52
Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/macrophage colony-stimulating factor. J Exp Med (1996) 1.36
Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev (1997) 1.32
Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis (2005) 1.32
On the refractory period of muscle and nerve. J Physiol (1909) 1.29
Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood (2001) 1.29
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood (1996) 1.26
Quantitative researches on the summation of inadequate stimuli in muscle and nerve, with observations on the time-factor in electric excitation. J Physiol (1910) 1.26
The linkage between T-cell and dendritic cell development in the mouse thymus. Immunol Rev (1998) 1.24
On the optimal electric stimuli of muscle and nerve. J Physiol (1906) 1.23
Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol (1999) 1.22
Temperature and excitability. J Physiol (1907) 1.17
On the gradation of activity in a skeletal muscle-fibre. J Physiol (1905) 1.15
Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood (1997) 1.12
Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant (1995) 1.10
Differential expression and regulation of the human CD8 alpha and CD8 beta chains. Tissue Antigens (1990) 1.08
[Contribution to the etiology of vagina prolapsus in pregnant cows (author's transl)]. Dtsch Tierarztl Wochenschr (1978) 1.07
High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors. J Neurooncol (1999) 1.06
Gastrointestinal parasites of shepherd and hunting dogs in the Serres Prefecture, Northern Greece. Vet Parasitol (2007) 1.05
M241 (CD1) expression on B lymphocytes. J Immunol (1987) 1.04
The relationship between temporomandibular disorders and stress-associated syndromes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1998) 1.03
Mycobacterium haemophilum infections in bone marrow transplant recipients. Transplantation (1995) 1.02
Absence of interleukin 2 production in a severe combined immunodeficiency disease syndrome with T cells. J Exp Med (1990) 1.01
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant (2007) 1.01
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. Blood (1989) 1.01
The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease. Immunodefic Rev (1989) 0.99
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. Br J Haematol (2000) 0.99
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant (2010) 0.98
Identification of a carcinoembryonic antigen gene family in the rat. Analysis of the N-terminal domains reveals immunoglobulin-like, hypervariable regions. J Biol Chem (1989) 0.98
Expression of HLA-DR antigen and characterization of the lymphocytic infiltrate in normal mucosa, tubulo-villous adenoma and invasive carcinoma of the colon. Chirurgia (Bucur) (2005) 0.97
The role of targeted selective treatments in the development of refugia-based approaches to the control of gastrointestinal nematodes of small ruminants. Vet Parasitol (2009) 0.97
Effect of halofuginone lactate on treatment and prevention of lamb cryptosporidiosis: an extensive field trial. J Vet Pharmacol Ther (2007) 0.96
Surgical management of cecal diverticulitis: is diverticulectomy enough? Int J Colorectal Dis (2004) 0.96
Amplification of IS6110 sequence for detection of Mycobacterium tuberculosis complex in HIV-negative patients with fever of unknown origin (FUO) and evidence of extrapulmonary disease. J Intern Med (2000) 0.95
Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol (1999) 0.94
Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood (1992) 0.94
Effects of sarcoptic mange on the reproductive performance of ewes and transmission of Sarcoptes scabiei to newborn lambs. Vet Parasitol (2001) 0.93
Acute coenurosis of dairy sheep from 11 flocks in Greece. N Z Vet J (2012) 0.93
High-frequency electric field trapping of individual human spermatozoa. Hum Reprod (1998) 0.92
Barriers to mental health service use among hematopoietic SCT survivors. Bone Marrow Transplant (2009) 0.92
Health management of ewes during pregnancy. Anim Reprod Sci (2012) 0.89
Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res (1990) 0.88
Adolescent girls' constructions of smoking identities: implications for health promotion. J Adolesc (1997) 0.88
Foot care education in patients with diabetes at low risk of complications: a consensus statement. Diabet Med (2011) 0.87
Long-term evaluation of patients with hydatidosis treated with albendazole and praziquantel. Int J Immunopathol Pharmacol (2008) 0.87
Uricase from soybean root nodules: purification, properties, and comparison with the enzyme from cowpea. Arch Biochem Biophys (1983) 0.87
Identifying patient-reported outcomes in rheumatoid arthritis: the impact of foot symptoms on self-perceived quality of life. Musculoskeletal Care (2012) 0.87
Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation. Bone Marrow Transplant (2007) 0.86
Bromide measurement in serum and urine by an improved gas chromatographic method. J Chromatogr (1979) 0.86
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant (2000) 0.86
Comparison of foot pain and foot care among rheumatoid arthritis patients taking and not taking anti-TNFα therapy: an epidemiological study. Rheumatol Int (2010) 0.85
Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol (1999) 0.85
High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol (1998) 0.85
Involvement of NK cells against tumors and parasites. Int J Biol Markers (2007) 0.85
ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7. Cell Immunol (1994) 0.84
Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial). Bone Marrow Transplant (2009) 0.83
Efficacy of moxidectin against sarcoptic mange and effects on milk yield of ewes and growth of lambs. Vet Parasitol (2000) 0.83
Hydatidosis of food animals in Greece: prevalence of cysts containing viable protoscoleces. J Helminthol (1994) 0.83
Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis. Bone Marrow Transplant (1997) 0.83
Myiasis in a dog shelter in Greece: epidemiological and clinical features and therapeutic considerations. Vet Parasitol (2011) 0.82
Analysis of HLA-D locus alleles in alopecia areata patients and families. J Invest Dermatol (1995) 0.82
Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant (2002) 0.82
Development of dendritic cells in culture from human and murine thymic precursor cells. Cell Mol Biol (Noisy-le-grand) (2001) 0.81
Legionella jordanis in hematopoietic SCT patients radiographically mimicking invasive mold infection. Bone Marrow Transplant (2011) 0.81
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol (2017) 0.80
Two mutational hotspots in the interleukin-2 receptor gamma chain gene causing human X-linked severe combined immunodeficiency. Am J Hum Genet (1995) 0.80
Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant (1997) 0.80
Assessment of dietary supplementation with probiotics on performance, intestinal morphology and microflora of chickens infected with Eimeria tenella. Vet Parasitol (2012) 0.80
G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant (2012) 0.80
Congenital disorder of true cyclopia with polydactylia: case report and review of the literature. Clin Exp Obstet Gynecol (2013) 0.80
cDNA and gene analyses imply a novel structure for a rat carcinoembryonic antigen-related protein. J Biol Chem (1990) 0.80
The use of targeted selective treatments against gastrointestinal nematodes in milking sheep and goats in Greece based on parasitological and performance criteria. Vet Parasitol (2009) 0.79
T-cell-depleted hematopoietic SCT from unrelated donors for the treatment of congenital amegakaryocytic thrombocytopenia. Bone Marrow Transplant (2011) 0.79
Effects of three anthelmintic regimes on milk yield of ewes and growth of lambs. J Vet Med A Physiol Pathol Clin Med (2005) 0.79
Live (vaccines) from New York. Bone Marrow Transplant (2012) 0.79
Spatiotemporal expression of pregnancy-specific glycoprotein gene rnCGM1 in rat placenta. Dev Dyn (1993) 0.79
Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C. Bone Marrow Transplant (2002) 0.79
On the influence of tension upon the contraction of skeletal muscle at high temperatures. J Physiol (1904) 0.78